跳至主要内容
临床试验/ACTRN12621000928819
ACTRN12621000928819招募中未知

Cessation Of Pharmacotherapy In Recovered Chemotherapy induced cardioToxicity (COP-RCT) – a pilot study

epean Blue Mountains Local Health District0 个研究点目标入组 70 人开始时间: 2021年7月15日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
17 Years 至 80 Years(—)
性别
All

入选标准

  • Previously diagnosed asymptomatic chemotherapy related cardiac dysfunction (CTRCD) (defined as: LVEF drop >10% to a value below <55% from baseline or GLS drop greater than or equal to 12% from baseline)
  • LVEF of >50%.
  • NYHA Class I
  • Current CTRCD therapy – Angiotensin Converting Enzyme inhibitor (ACEi) AND/OR Beta Blocker (BB)
  • Completed HER2 receptor therapy (traztuzumab/pertuzumab)

排除标准

  • History of ischaemic heart disease
  • Hypertension requiring medical therapy
  • Moderate or greater severity valvular disease
  • Chronic kidney disease
  • Atrial, supraventricular, or ventricular arrhythmia requiring BB therapy
  • Pregnancy
  • < 16 years old

研究者

发起方
epean Blue Mountains Local Health District

相似试验

Cessation Of Pharmacotherapy In Recovered... | 临床试验